Cardlytics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cardlytics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $233.27M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $278.30M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $309.20M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $298.54M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $267.12M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $186.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $210.43M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | $150.68M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $130.37M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $112.82M | Mar 5, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.33M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $255.61M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $285.43M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $277.19M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $258.75M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $186.89M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $210.43M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | $150.68M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $130.37M | Mar 3, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($103.49M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($189.30M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($134.70M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($465.26M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($128.57M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($55.42M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($17.14M) | May 2, 2022 |
| FY2020 | Dec 31, 2018 | ($53.04M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($19.64M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($75.70M) | Mar 5, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($101.82M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($195.50M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($135.67M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($457.78M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($122.60M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($53.92M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($17.33M) | May 2, 2022 |
| FY2020 | Dec 31, 2018 | ($40.92M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($17.10M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($56.23M) | Mar 5, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.77M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $49.61M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $51.35M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $54.44M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $38.10M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $17.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $11.70M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | $16.21M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $12.15M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $13.90M | Mar 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.29M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($8.82M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($185.0K) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($53.90M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | ($38.52M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($7.60M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $11.46M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | ($19.00M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($22.10M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($32.50M) | Mar 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.0K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.56M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $667.0K | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $1.17M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $3.11M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $5.41M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $8.28M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | $5.92M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.22M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $1.83M | Mar 5, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $285.64M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $392.71M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $574.14M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $691.24M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.26B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $422.54M | May 2, 2022 |
| FY2020 | Dec 31, 2019 | $224.31M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $153.76M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $100.76M | Mar 5, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $292.15M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $322.72M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $439.35M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $479.63M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $573.10M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $265.35M | May 2, 2022 |
| FY2020 | Dec 31, 2019 | $81.05M | Mar 1, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.51M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $69.99M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $134.80M | Mar 4, 2026 |
| FY2025 | Dec 31, 2022 | $211.61M | Mar 4, 2026 |
| FY2024 | Dec 31, 2021 | $690.70M | Mar 12, 2025 |
| FY2023 | Dec 31, 2020 | $157.19M | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | $143.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $51.98M | May 2, 2022 |
| FY2020 | Dec 31, 2017 | ($208.69M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($216.84M) | Mar 3, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $110.31M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $159.43M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $277.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2022 | $352.72M | Mar 4, 2026 |
| FY2024 | Dec 31, 2021 | $742.52M | Mar 12, 2025 |
| FY2023 | Dec 31, 2020 | $0 | Mar 14, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.40B) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($1.30B) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($1.11B) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($976.57M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($522.62M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($394.05M) | May 2, 2022 |
| FY2020 | Dec 31, 2019 | ($338.63M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($321.49M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($268.45M) | Mar 5, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.72M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $65.59M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $91.83M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $121.91M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $233.47M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $293.24M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $104.46M | May 2, 2022 |
| FY2020 | Dec 31, 2018 | $39.62M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $21.26M | Mar 3, 2020 |
| FY2018 | Sep 30, 2017 | $39.62M | Mar 5, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.57M | Mar 4, 2026 |
| FY2024 | Dec 31, 2024 | $218.57M | Mar 12, 2025 |
| FY2022 | Dec 31, 2022 | $226.04M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $184.40M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $174.01M | Mar 1, 2022 |
| FY2020 | Sep 22, 2020 | $174.01M | Mar 1, 2021 |
| FY2018 | Dec 31, 2018 | $46.66M | Mar 5, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | (13) | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | (3) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 1, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | (13) | Mar 12, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 54.51M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 51.26M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 39.73M | Mar 12, 2025 |
| FY2018 | Dec 31, 2018 | 22.47M | Mar 5, 2019 |
| FY2018 | Dec 31, 2017 | 3.44M | Mar 5, 2019 |